Article Versions Notes

Sütering T, Bode SFN, Fischer R, Fabricius D. Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI). Advances in Respiratory Medicine. 2024; 92(6):559-572. https://doi.org/10.3390/arm92060049

Sütering, Tomke, Sebastian F. N. Bode, Rainald Fischer, and Dorit Fabricius. 2024. "Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI)" Advances in Respiratory Medicine 92, no. 6: 559-572. https://doi.org/10.3390/arm92060049

Sütering, T., Bode, S. F. N., Fischer, R., & Fabricius, D. (2024). Successful Therapy over 12 Months of People with Cystic Fibrosis with Rare Non-phe508del Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations with Elexacaftor/Tezacaftor/Ivacaftor (ETI). Advances in Respiratory Medicine, 92(6), 559-572. https://doi.org/10.3390/arm92060049